Medline resumed with a Buy at Citi
Citi resumed coverage of Medline (MDLN) with a Buy rating and $60 price target following a period of suspension. The company’s Q4 report came in well ahead of expectations on broad-based strength, the analyst tells investors in a research note. Citi believes Medline has a “compelling set-up” into fiscal 2026 as a “safety trade.”
Read More on MDLN:
- Medline price target raised to $53 from $50 at JPMorgan
- Medline price target raised to $60 from $55 at Tigress Financial
- Medline 75M share Secondary priced at $41.00
- Medline announces launch of secondary offering of Class A common stock
- Medline files to sell 75M shares of Class A common stock for holders
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cathie Wood Blames Anthropic’s CEO for AI Panic: Why Attack a Company Her Fund Backs?
Anthropic's $1.5 Trillion IPO: What Investors Should Know Before Buying
Why is the US Dollar Falling? Midterms, Yields, and a Critical Economic Test
Bitcoin and Nvidia are Losing to Restaurant Chain Stocks in 2026
Crypto prices
More
